1. Japan Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Sugi Holdings Co.,Ltd.

Sugi Holdings Co.,Ltd.

SGIPF
Sugi Holdings Co.,Ltd.US flagOther OTC
18.99
USD
- -
- -
3.44BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
1,922.63
2,019.75
2,184.24
2,268.01
2,406.24
2,611.43
2,922.55
3,250.89
3,372.92
3,689.56
4,114.12
4,852.03
5,582.88
4,375.61
Basic EPS, GAAP
67.49
67.71
76.89
78.69
86.4
95.91
112.07
113.89
104.56
105.04
121.46
141.96
248.56
136.91
Free Cash Flow per Basic Share
53.01
128.8
15.75
26.46
83.41
25.75
134.63
67.21
-87.39
92.66
35.04
60.26
337.25
- -
Dividend per Share
10.32
14.65
13.34
16.66
16.67
23.41
24.99
26.66
26.66
27.14
26.66
28.33
34.97
- -
Book Value per Share
474.75
527.8
592.32
654.35
724.09
807.79
901.85
989.08
1,066.98
1,158.23
1,253.03
1,366.64
1,580.11
1,311.98
Tangible Book Value per Share
593.26
637.55
704.08
766.22
837.52
874.45
966.37
1,053.18
1,117.75
1,151.75
1,232.37
1,097.45
1,320.29
1,289.3
Basic Weighted Avg Shares
190
190
190
190
190
187
185
185
185
181
181
181
181
181
Sales/Revenue/Turnover
365,200
383,644
414,885
430,795
457,047
488,464
541,964
602,850
625,477
667,647
744,477
878,021
1,010,336
791,722
Operating Margin (%)
5.51
5.44
5.57
5.3
5.42
5.29
5.49
5.65
5.14
4.74
4.92
4.85
4.81
5
Depreciation Expense
4,994
4,952
5,267
5,599
6,455
7,389
8,412
9,940
11,268
12,362
14,179
17,871
20,110
- -
Net Income, GAAP
12,820
12,862
14,605
14,947
16,411
17,940
20,782
21,120
19,389
19,007
21,979
25,689
44,982
24,773
Effective Tax Rate (%)
39.49
38.42
36.02
33.63
33.17
31.14
30.56
32.99
29.38
32.56
31.53
32.53
0.43
31.99
Profit Margin (%)
3.51
3.35
3.52
3.47
3.59
3.67
3.83
3.5
3.1
2.85
2.95
2.93
4.45
3.13
Working Capital
65,613
73,655
80,959
86,717
94,049
83,938
81,104
85,480
89,869
82,969
62,398
30,400
79,442
62,879
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
521
2,064
67,193
406
Total Equity
114,808
124,281
136,783
148,781
162,046
166,562
182,748
200,629
213,888
216,537
233,361
250,704
290,473
243,609
Return on Invested Capital (%)
10.8
10.41
10.97
10.39
10.42
10.53
11.52
11.54
10.74
9.77
10.84
10.53
13.97
11
Return on Capital (%)
15.14
13.52
13.74
12.64
12.55
12.44
13.07
12.05
10.18
9.34
10.06
9.93
13.64
10.63
Return on Common Equity (%)
15.13
13.51
13.73
12.62
12.54
12.43
13.06
12.05
10.17
9.33
10.07
10.84
16.87
10.89

Capital Structure

FRC

•

in mil. unless spec.
Feb'24
May'25
Aug'25
ST Debt
316
10,816
10,771
LT Borrowings
521
439
406
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
181
181
181
Market Capitalization
418,848
463,736
430,985

Working Capital

FRC

•

in mil. unless spec.
Feb'24
May'25
Aug'25
Total Current Assets
199,046
207,732
244,528
Cash, Cash Equivalents & STI
47,427
48,732
78,181
Accounts Receivable, Net
44,376
48,815
51,795
Inventories
83,679
86,414
83,514
Total Current Liabilities
136,648
150,890
181,649
Payables & Accruals
- -
- -
- -
ST Debt
316
10,816
10,771
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.89%
7.78%
15.86%
Free Cash Flow
61.8%
7.2%
459.68%
Net Income, GAAP
13.64%
19.49%
75.1%
Sales/Revenue/Turnover
9.4%
11%
15.07%
Total Cash Common Dividend
- -
- -
23.44%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
200,959
212,850
- -
- -
878,021
2026
- -
- -
- -
- -
1,010,336
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
33.84
- -
- -
- -
141.96
2026
- -
- -
- -
- -
248.56
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
28.33
2026
- -
- -
- -
- -
34.97
2027
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Katsunori Sugiura
Full Time Employees
13,417
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Address
62-1 Shine Yokonemachi Obu AI Japan 474-0011
IPO Date
Feb 18, 2020
CIK
0002027330
Website
sugi-hd.co.jp
Similar Companies
Bacil Pharma Limited (BACPHAR.BO)
Alar Pharmaceuticals Inc. (6785.TWO)
Irwin Naturals Inc. (IWIN.CN)
Quest Laboratories Ltd. (QUESTLAB.NS)
Ligand Pharmaceuticals, Inc. (LGNZZ)
Shire plc (SHPG)
Business
Sugi Holdings Co., Ltd., a Japan-based holding company founded in December 1976 and headquartered in Obu-City, Aichi, manages the SUGI Pharmacy Group, which operates approximately 2,300 drugstores across Japan focused on community medical care support; the group provides prescription dispensing services handling nearly 20 million prescriptions annually, over-the-counter pharmaceutical sales, health foods, cosmetics, daily necessities, and pet supplies; it offers self-care support including meal delivery, cancer checkups, specific health guidance by nationally certified dieticians, home-visit nursing, mobility and shopping assistance for seniors, preventive programs, and digital health tools like lifestyle disease risk reports; subsidiaries such as SUGI Pharmacy, Hanshin Dispensing, NIHONDO for Kampo medicine counseling, Sugi Wellness for disease prevention services to insurers and individuals, SUGI Medical for medical coordination and visiting nursing stations, and S Trading for Asian market expansion provide specialized healthcare, dispensing, and wholesale operations primarily in Kanto, Chubu, Kansai, Hokuriku, and extending to Hokkaido and Kyushu regions. The company employs 11,820 people consolidated and reported net sales of 878 billion yen for the fiscal year ended February 2025. In recent developments, Sugi Holdings acquired a 34.8% stake in Seki Yakuhin Co., Ltd. in 2025 with plans to increase to 49% for enhanced community healthcare synergies and store network dominance; it expanded into Southeast Asia through a 2024 memorandum with Thailand's PTT Oil and Retail Business Public Co., Ltd., a joint venture with Malaysia's ALPRO ALLIANCE SDN. BHD. in 2023, and partnerships with Vietnam's Omicare and Taiwan's Great Tree Pharmacy; additional moves include acquiring shares in I&H Co., Ltd. and NIHONDO Co., Ltd. as subsidiaries in 2024 and 2023 respectively, forming a joint venture with BLEZ ASIA Co., Ltd. in 2025 for Asian product supply, signing a deal with AC Health in the Philippines, and expanding renewable energy PPAs with Clean Energy Connect to cover 65 stores. The group continues to grow store count, reaching 2,279 by August 2025 with nine new openings that month and 2.4% existing store sales growth, while advancing total healthcare strategies including ICT systems and epilepsy support via KNOCK ON THE DOOR Inc..